Biocon Performance degli utili passati
Criteri Il passato verificati 1/6
Biocon ha registrato una crescita degli utili a un tasso medio annuo di 2.7%, mentre il settore Biotechs ha registrato utili in crescita a un tasso medio annuo di 14.3%. I ricavi sono stati in crescita a un tasso medio annuo di 18.5%. Il ritorno sul capitale proprio di Biocon è 1% e ha margini netti di 2.3%.
Informazioni chiave
2.69%
Tasso di crescita degli utili
1.89%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 5.13% |
| Tasso di crescita dei ricavi | 18.53% |
| Rendimento del capitale proprio | 1.01% |
| Margine netto | 2.28% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Articolo di analisi • May 21
Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...Articolo di analisi • Nov 19
Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)
The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...Recent updates
Articolo di analisi • May 21
Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...
Aggiornamento della narrazione • May 03
BIOCON: Leadership Changes And Biosimilars Expansion Will Support Future Upside
Biocon's analyst price target has been trimmed slightly to about ₹416 from roughly ₹421 as analysts factor in a marginally higher discount rate, slightly softer revenue growth and profit margin assumptions, partly balanced by a modestly higher future P/E multiple. Analyst Commentary Recent Street research around comparable life sciences names points to a cautious tone on execution risk, revenue trajectory and the willingness of the market to pay up for growth after guidance disappointments.
Aggiornamento della narrazione • Apr 19
BIOCON: Higher Profitability Assumptions Will Support U.S. Biosimilars And GLP-1 Entry
Narrative Update on Biocon Analysts have adjusted their price target on Biocon to ₹544, up from ₹465. This reflects updated assumptions around a higher fair value estimate, revised profit margin expectations, and a slightly different discount rate and forward P/E framework.Aggiornamento della narrazione • Apr 05
BIOCON: Leadership Refresh And Biosimilars Integration Will Support Future Upside
Analysts have trimmed Biocon's fair value estimate slightly to ₹420.74 from ₹421.60, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts are treating the trimmed fair value estimate as a fine tuning of expectations rather than a major reset, with views split between what could support upside and what might cap near term returns.
Aggiornamento della narrazione • Mar 21
BIOCON: Limited P/E Expansion Will Constrain Returns Despite New Metabolic Drug Approvals
Analysts have trimmed their Biocon price target slightly to about ₹295.70 from roughly ₹297.40, reflecting a modest recalibration of fair value, discount rate and long term assumptions for revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts trimming Biocon's fair value signal a more careful stance on what they are willing to pay for the shares today, given reassessed views on growth, profitability and valuation multiples.Aggiornamento della narrazione • Mar 07
BIOCON: Limited Multiple Expansion Will Constrain Returns Despite New GLP 1 Approvals
Narrative update Analysts have trimmed their Biocon price target slightly to about ₹297 from roughly ₹298, reflecting updated assumptions on discount rate, revenue growth, profit margins and future P/E multiples after recent sector research signalled a more cautious stance on multiple expansion. Analyst Commentary Bearish analysts looking at global life sciences peers have trimmed price targets after recent earnings misses and cautious forward commentary, and those moves are informing how some investors think about Biocon's risk and valuation setup.Aggiornamento della narrazione • Feb 21
BIOCON: Execution And Multiple Compression Risks Will Restrain Future Share Returns
Analysts have inched up their Biocon fair value estimate to about ₹298 per share from roughly ₹295, reflecting slightly lower discount rate assumptions, modestly softer revenue growth expectations, a somewhat stronger profit margin outlook, and a marginally reduced future P/E multiple. Analyst Commentary While the fair value adjustment for Biocon is modest, some bearish analysts are still flagging risks that could cap upside in the near term.Aggiornamento della narrazione • Feb 07
BIOCON: Equity Dilution And Biosimilars Review Will Pressure Future Returns
Analysts have slightly reduced their Biocon fair value estimate to ₹295.12 from ₹296.78, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Biocon completed a follow on equity offering of equity shares worth ₹41.5b, issuing 112,664,585 common shares at ₹368.35 each under a Regulation S structure with a subsequent direct listing (company filing).Aggiornamento della narrazione • Jan 23
BIOCON: Biosimilars Reorganisation And GLP 1 Expansion Will Drive Future Upside
Analysts have nudged their fair value estimate for Biocon higher from ₹412.05 to ₹421.60, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Biocon completed a follow on equity offering of ₹41.5b, issuing 112,664,585 equity shares at ₹368.35 per share under Regulation S, followed by a subsequent direct listing (Key Developments).Aggiornamento della narrazione • Jan 09
BIOCON: Planned Capital Raise Will Likely Weigh On Future Shareholder Returns
Analysts have lifted their price target on Biocon from ₹290.00 to about ₹296.78, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E inputs in their models. What's in the News Shareholders approved amendments to Biocon's Articles of Association at the AGM held on December 31, 2025, signaling changes to the company's governing documents (Key Developments).Aggiornamento della narrazione • Dec 26
BIOCON: Future Equity Issuance Will Likely Pressure Shareholder Returns
Analysts have maintained their fair value estimate for Biocon at ₹290.00 per share, with only minor model adjustments to discount rate, revenue growth, and profit margin assumptions. These changes have resulted in no alteration to their overall price target, as they continue to view the company’s long term earnings profile as broadly intact.Articolo di analisi • Dec 25
Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Biocon fair value estimate is ₹364 With ₹398 share price...Aggiornamento della narrazione • Dec 12
BIOCON: Future Share Dilution Risk Will Likely Pressure Returns
Analysts have raised their price target on Biocon from ₹277.50 to ₹290.00, reflecting higher anticipated revenue growth, improved profit margins, and a modestly re-rated future P E multiple despite a slightly higher discount rate. What's in the News Biocon is exploring strategic options for its biosimilars arm Biocon Biologics Limited, including a potential merger with the parent company in place of an IPO, with Morgan Stanley advising on value creation alternatives (Key Developments).Articolo di analisi • Dec 07
Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel
You may think that with a price-to-sales (or "P/S") ratio of 3.2x Biocon Limited ( NSE:BIOCON ) is a stock worth...Aggiornamento della narrazione • Nov 27
BIOCON: Global Expansion And Business Restructuring Are Expected To Balance Opportunities And Risks
Analysts have raised their price target for Biocon from ₹395.65 to ₹412.05. This change reflects updated expectations around key valuation inputs and profitability metrics.Articolo di analisi • Nov 19
Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)
The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...Aggiornamento della narrazione • Nov 13
BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance
Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.Aggiornamento della narrazione • Oct 05
Biosimilars Demand Will Unlock Global Market Opportunities
Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.Articolo di analisi • Sep 22
Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price
Key Insights The projected fair value for Biocon is ₹577 based on 2 Stage Free Cash Flow to Equity Biocon's ₹369 share...Articolo di analisi • Aug 10
Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models
NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...Articolo di analisi • Aug 04
Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now
Biocon Limited's ( NSE:BIOCON ) price-to-earnings (or "P/E") ratio of 50.5x might make it look like a strong sell right...Articolo di analisi • Jun 19
Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next
Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...Articolo di analisi • Jun 18
Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50
The board of Biocon Limited ( NSE:BIOCON ) has announced that it will pay a dividend on the 5th of September, with...
Nuova narrazione • Dec 12
Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability
Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Biocon guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 169,270 | 3,856 | 35,080 | -1,137 |
| 31 Dec 25 | 168,274 | 6,042 | 37,604 | -1,379 |
| 30 Sep 25 | 164,758 | 4,855 | 36,090 | -1,189 |
| 30 Jun 25 | 157,707 | 3,850 | 35,755 | -1,501 |
| 31 Mar 25 | 152,617 | 10,133 | 34,978 | -1,476 |
| 31 Dec 24 | 147,618 | 8,043 | 32,633 | -1,843 |
| 30 Sep 24 | 148,941 | 14,392 | 34,323 | -1,515 |
| 30 Jun 24 | 147,660 | 15,808 | 30,286 | -1,110 |
| 31 Mar 24 | 147,557 | 10,225 | 28,525 | -838 |
| 31 Dec 23 | 146,125 | 12,002 | 26,439 | -119 |
| 30 Sep 23 | 135,999 | 4,984 | 24,819 | -1,238 |
| 30 Jun 23 | 124,573 | 4,197 | 23,998 | -2,156 |
| 31 Mar 23 | 111,742 | 4,627 | 23,331 | -3,922 |
| 31 Dec 22 | 98,091 | 3,881 | 22,558 | -5,606 |
| 30 Sep 22 | 90,422 | 6,170 | 21,920 | -5,825 |
| 30 Jun 22 | 85,629 | 7,084 | 21,305 | -5,768 |
| 31 Mar 22 | 81,840 | 6,484 | 20,539 | -4,764 |
| 31 Dec 21 | 75,800 | 6,727 | 20,252 | -4,050 |
| 30 Sep 21 | 72,632 | 6,542 | 19,935 | -3,581 |
| 30 Jun 21 | 71,726 | 6,852 | 19,466 | -3,530 |
| 31 Mar 21 | 71,431 | 7,405 | 17,485 | -3,507 |
| 31 Dec 20 | 68,913 | 5,996 | 16,778 | -3,607 |
| 30 Sep 20 | 67,571 | 6,362 | 15,906 | -3,596 |
| 30 Jun 20 | 65,796 | 6,870 | 15,120 | -3,568 |
| 31 Mar 20 | 63,005 | 7,771 | 16,545 | -3,458 |
| 31 Dec 19 | 63,150 | 8,385 | 13,910 | -3,001 |
| 30 Sep 19 | 61,077 | 8,529 | 13,093 | -2,746 |
| 30 Jun 19 | 58,565 | 9,919 | 12,449 | -2,757 |
| 31 Mar 19 | 55,144 | 9,053 | 11,653 | -2,699 |
| 31 Dec 18 | 51,551 | 8,220 | 11,087 | -2,421 |
| 30 Sep 18 | 46,722 | 6,967 | 10,496 | -2,449 |
| 30 Jun 18 | 43,198 | 4,108 | 9,862 | -1,993 |
| 31 Mar 18 | 41,234 | 3,724 | 9,311 | -1,747 |
| 31 Dec 17 | 38,792 | 3,695 | 8,708 | -1,522 |
| 30 Sep 17 | 38,589 | 4,489 | 8,297 | -1,257 |
| 30 Jun 17 | 38,361 | 5,268 | 7,846 | -1,324 |
| 31 Mar 17 | 38,911 | 6,121 | 7,510 | -1,283 |
| 31 Dec 16 | 40,487 | 11,633 | 7,458 | -1,472 |
| 30 Sep 16 | 38,110 | 10,961 | 7,038 | -1,468 |
| 30 Jun 16 | 36,539 | 9,388 | 6,665 | -1,378 |
| 31 Mar 16 | 33,474 | 5,504 | 6,128 | -1,320 |
| 31 Dec 15 | 32,997 | 7,367 | 8,595 | -202 |
| 30 Sep 15 | 32,325 | 7,247 | 8,366 | -196 |
| 30 Jun 15 | 31,528 | 5,207 | 8,223 | -272 |
Guadagni di qualità: BIOCON ha un grande una tantum perdita di ₹4.0B che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 31st March, 2026.
Margine di profitto in crescita: Gli attuali margini di profitto netti di BIOCON (2.3%) sono inferiori rispetto allo scorso anno (6.6%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di BIOCON sono cresciuti del 2.7% all'anno negli ultimi 5 anni.
Accelerare la crescita: BIOCON ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.
Guadagni vs Settore: BIOCON ha avuto una crescita negativa degli utili ( -61.9% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Biotechs ( 4.3% ).
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 1% ) di BIOCON è considerato basso.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/22 19:29 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Biocon Limited è coperta da 39 analisti. 18 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Meeta Shetty | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |